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Abstract
Background: Susceptibility testing of pyrazinamide (PZA) against Mycobacterium tuberculosis is difficult to perform
because the acidity of culture medium that is required for drug activity also inhibits the growth of bacteria. In
Thailand, very limited information has been generated on PZA resistance, particularly among multidrug-resistant
tuberculosis (MDR-TB) isolated from Thailand. Only two studies on PZA susceptibility among Thai M. tuberculosis
strains have been reported; one used a pyrazinamidase assay, and the other used the BACTEC 460 TB for PZA
susceptibility testing. In this study, we determined the percentage of strains possessing pyrazinamide resistance
among pan-susceptible M. tuberculosis and MDR-TB isolates by using the pyrazinamidase assay, BACTEC MGIT 960
PZA method and pncA sequencing, and assessed the correlation in the data generated using these methods. The
type and frequency of mutations in pncA were also determined.
Results: Overall, 150 M. tuberculosis isolates, consisting of 50 susceptible and 100 MDR-TB isolates, were tested for
PZA susceptibility by BACTEC MGIT 960 PZA, the pyrazinamidase assay and pncA sequencing. The study indicated
PZA resistance in 6% and 49% of susceptible and MDR-TB isolates, respectively. In comparison to the BACTEC MGIT
960 PZA, the PZase assay showed 65.4% sensitivity and 100% specificity, whereas pncA sequencing showed 75%
sensitivity and 89.8% specificity. Twenty-four mutation types were found in this study, with the most frequent
mutation (16%) being His71Asp. Of these mutations, eight have not been previously described. The Ile31Ser and
Ile31Thr mutations were found both in PZA susceptible and resistant isolates, suggesting that mutation of this
codon might not play a role on PZA resistance.
Conclusions: Our findings suggest that phenotypic susceptibility testing is still essential for the detection of PZA
resistance, especially for MDR-TB isolates. Some mutations were not associated with resistance and could lead to
misinterpretation of the genotypic methods. This information could be helpful for clinicians in managing
tuberculosis patients and frequencies, and the types of pncA mutations should offer baseline information on PZA
resistance.
Background
Tuberculosis (TB) is a public health problem caused by
Mycobacterium tuberculosis. Thailand was ranked 18
th
among high-burden countries, with 91,000 cases per
year and new cases of MDR-TB (resistance to at least
isoniazid and rifampicin) of approximately 1.7% [1].
Tuberculosis infection is increasing in human immuno-
deficiency virus (HIV) co-infected patients, affecting the
TB control program as about one-third of Thai HIV/
AIDS patients present with active TB [2-5]. The stan-
dard regimen for the treatment of TB consists of 2
months of intensive treatment with isoniazid, rifampicin,
ethambutol, and pyrazinamide (H, R, E, and Z), followed
by 4 months of maintenance treatment with isoniazid
and rifampicin (H and R). Whereas other first-line drugs
do not reveal any problem for susceptibility testing, this
is not true for pyrazinamide, as it is active against tuber-
cle bacilli only at an acidic pH (e.g., pH 5.5), resulting in
that it cannot use conventional culture medium for sus-
ceptibility testing [6].
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version to the active form, pyrazinoic acid (POA), by
mycobacterial pyrazinamidase (PZase) [7]. The exact tar-
get of POA is unknown. It has been suggested that the
accumulation of POA in acidic conditions (from lactic
acid produced by inflammation cells) leads to acidifica-
tion of the cytoplasm and subsequent cell damage [7,8].
Mycobacterial pyrazinamidase is encoded by pncA,a n d
mutations in this gene have been demonstrated as the
major mechanism of PZA resistance [9]. Several muta-
tions, including missense, insertion, deletion and non-
sense mutations, have been reported and located in both
the putative promoter and coding regions of pncA [10].
PZA-resistant M. tuberculosis strains are usually corre-
lated with defective PZase activity, but some PZA resis-
tant strains have been reported to contain wild-type
pncA and to maintain PZase activity [11-14], suggesting
that other unknown resistance mechanisms could be
responsible for the resistance phenotype.
PZA susceptibility testing is difficult because the acid-
ity of culture medium needed for drug activity also
restricts the growth of M. tuberculosis.T h eu s eo fl a r g e
inoculum sizes results in the release of NH3, leading to
increased pH and inactivated PZA [7]. The BACTEC
460 TB radiometric method has been validated and
developed as the reference method for PZA susceptibil-
ity testing [15]. Recently, PZA susceptibility testing has
been performed by the nonradiometric, fully automated,
continuous-monitoring MGIT 960 system (Becton Dick-
inson), which produced a rapid and reliable result
[16,17]. Many studies revealed a good correlation
between loss of PZase activity and resistance to PZA
[18-22]. Thus, the detection of PZase activity has been
used for PZA susceptibility testing. Nevertheless, various
levels of sensitivity (79-96%) of the PZase assay for PZA
susceptibility testing have been reported [20-22]. In
Thailand, only two studies on PZA susceptibility among
Thai M. tuberculosis strains have been reported, and the
r e s u l t sr e v e a l e dt h a tt h ei n itial PZA resistance was
5.95% and 7.8% when detected by the PZase assay [18]
and by BACTEC 460 TB [23], respectively. In this study,
we determined the percentage of strains that exhibited
pyrazinamide resistance among pan-susceptible M.
tuberculosis and MDR-TB isolates by using the pyrazi-
namidase assay, BACTEC MGIT 960 PZA method and
pncA sequencing, and we evaluated the correlation of
the results obtained with these methods. pncA mutation
type and frequency were also evaluated.
Methods
Mycobacterial isolates
During 2005-2007, there were 4,536 M. tuberculosis
isolates from 7,807 sputum samples sending from all
parts of Thailand (118 hospitals and 43 of 76
provinces) to the Molecular Mycology and Mycobac-
teriology Laboratory, Drug-Resistant Tuberculosis
Research Fund, Department of Microbiology, Faculty
of Medicine Siriraj Hospital, Mahidol University. Of
these, 220 and 4,316 isolates were identified as MDR-
TB and non MDR-TB, including pan-susceptible
isolates respectively. One hundred and fifty M. tuber-
culosis clinical isolates, consisting of 50 pan-susceptible
isolates (susceptible to isoniazid, rifampicin, ethambu-
tol, and streptomycin) and 100 isolates of MDR-TB,
were selected based on their ability to re-cultivate
from stock cultures and availability of demographic
data. The MDR-TB isolates contain 17, 13, 26 and 44
isolates resisted to isoniazid and rifampicin, to isonia-
zid, rifampicin and streptomycin, to isoniazid, rifampi-
cin and ethambutol and to all four drugs respectively.
These isolates were identified to species using the in-
house one-tube multiplex PCR [24], and antimicrobial
susceptibility testing to isoniazid, rifampicin, ethambu-
tol and streptomycim was performed by the standard
proportion method on M7H10 agar as recommended
by the CDC [25] and NCCLS [15]. Each isolate
obtained from individual patient. The patients include
new and previously treated patients with the age ran-
ged from 5 to 81 years and comprised of 65% male
and 35% female. Only 21% were known human immu-
nodeficiency virus (HIV) status. Among these, 52%
were HIV-positive.
PZA susceptibility testing
Pyrazinamide susceptibility testing was performed using
the BACTEC MGIT 960 PZA system (Becton Dickin-
son) as recommended by the manufacturer. The med-
ium used was modified Middlebrook 7H9 broth (pH
5.9) containing 100 μg/ml PZA. Mycobacterium bovis
BCG ATCC 34540 and Mycobacterium tuberculosis
H37Rv ATCC 27294 were used as pyrazinamide resis-
tant and susceptible controls, respectively. The control
strains were included in all test sets.
Pyrazinamidase assay
Pyrazinamidase activity was determined by Wayne’s
method [26]. This method is based on the detection of
POA, which forms a compound with ferrous ammonium
sulphate to produce a brownish or pink colour. Briefly, a
heavy loopful of M. tuberculosis colonies was obtained
from cultures that were actively growing in LJ medium
and inoculated onto the surfaces of two agar butt tubes,
each containing 5 ml of Wayne’s medium supplemented
with 100 μg/ml of PZA (Sigma-Aldrich, USA). The
tubes were incubated at 37°C. Four days after incuba-
tion, 1 ml of freshly prepared 1% ferrous ammonium
sulphate was added to the first tube. The tube was left
at room temperature for 30 minutes and examined. The
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sent on the surface of the agar. If the test was negative,
the test was repeated with a second tube and examined
after 7 days of incubation. The results were blindly read
by two independent observers. M. bovis BCG and M.
tuberculosis H37Rv were used as negative and positive
controls, respectively.
DNA extraction
Mycobacterial DNAs were extracted by the boiling
method [27]. Briefly, one loopful of M. tuberculosis colo-
nies obtained from LJ medium was suspended in 200 μl
of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
and boiled for 20 minutes. The supernatant was col-
lected by centrifugation at 12,000 rpm for 5 min and
used as the DNA template for amplification.
Amplification and sequencing of the amplified pncA gene
The pncA forward primer, pncAF1, (5’-GCGGCG
TCATGGACCCTATATC-3’) was located 82 bp
upstream of the start codon, and the reverse primer,
pncAR1, (5’-CTTGCGGCGAGCG CTCCA -3’)w a s
located 54 bp downstream of the stop codon of M.
tuberculosis pncA (Rv2043c). The expected size of the
PCR products was 696 bp. PCR was performed in a
total volume of 50 μl, and the PCR reaction mixture
consisted of 0.25 mM dNTP (Fermentas, CA, USA),
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.0 mM MgCl2,
20 pmol of each primer, 1 unit of Taq DNA polymerase
(Fermentas, CA, USA) and 5 μlo fc r u d eD N A .T h e
PCR reactions were performed under the following con-
ditions: initial denaturation at 94°C for 5 min; 40 cycles
of denaturation at 94°C for 1 min, annealing at 62°C for
1 min and extension at 72°C for 1 min; and 1 final cycle
of extension at 72°C for 10 min. PCR products were
analysed by 1% agarose gel electrophoresis, and subse-
q u e n t l yt h e yw e r ep u r i f i e du s i n gt h eG e lE x t r a c t i o nK i t
(Qiagen, Germany). Finally, purified DNAs were directly
sequenced with the ABI PRISM 3730XL Analyzer,
(Applied Biosystems, Foster City, USA) using the
pncAF1 and pncAR1 primers as sequencing primers.
The obtained sequences were compared with the
sequence of M. tuberculosis H37Rv pncA (Accession no.
NC_000962) by using the blastn program http://blast.
ncbi.nlm.nih.gov/Blast.cgi.
Results
Pyrazinamide susceptibility testing by the phenotypic
method
MGIT 960 susceptibility testing demonstrated that 52
(34.6%) of 150 isolates were phenotypically resistant to
PZA. More specifically, 3 (6%) of 50 pan-susceptible M.
tuberculosis isolates were resistant to PZA, whereas 49
(49%) of 100 MDR-TB isolates were PZA-resistant, as
summarised in Table 1.
Correlation of PZA susceptibility testing and the
pyrazinamidase assay
Pyrazinamidase activity was detected in all pan-suscepti-
ble isolates and in 3 PZA-resistant isolates. Among the
100 MDR-TB isolates, 85 provided concordant results
between the two methods; 51 isolates with phenotypic
susceptibility to PZA had PZase activity, whereas PZase
activity could not be detected in 34 PZA-resistant iso-
lates. However, 15 MDR-TB isolates with PZA-resistant
phenotypes had PZase activity (Table 1). Compared to
the BACTEC MGIT 960 PZA system, the PZase assay
showed 65.4% sensitivity and 100% specificity.
Correlation of PZA susceptibility, pyrazinamidase assay
and mutations in pncA
Susceptibility testing by BACTEC MGIT 960 PZA
revealed 98 PZA-susceptible isolates with positive PZase
activity. Of these, 88 isolates had no mutations in pncA,
whereas 10 isolates harboured mutations at nucleotide
92 (T ® G/C), causing an amino acid change from iso-
leucine to serine or threonine, respectively, at codon 31.
Thirty-two of the PZA-resistant isolates without PZase
activity contained mutations in pncA,w i t h1 8t y p e so f
nucleotide substitutions in the coding region, 2 muta-
tional types in the putative promoter region, 2 nucleo-
tide insertions, and one nonsense mutation, as
summarised in Table 2. Interestingly, there were two
PZA-resistant isolates with negative PZase activity that
were mutated at codon 31 (Ile®Ser), a mutant that was
also found in PZA-susceptible isolates. In contrast, five
PZA-resistant isolates that had Ile31Ser or Ile31Thr
mutations possessed PZase activity (Table 2). Moreover,
there were 13 (26.5%) isolates with wild-type pncA and
PZase activity but possessed resistant phenotypes. Thus,
the sensitivity and specificity of pncA sequencing were
Table 1 Comparison of pncA sequencing, the pyrazinamidase assay, and the MGIT 960 system for PZA susceptibility
testing.
M. tb strains
(total no. of isolates)
MGIT (S)
PZase (pos)
pncA (wt)
MGIT (S)
PZase (pos)
pncA (mut)
MGIT (R)
PZase (neg)
pncA (mut)
MGIT (R)
PZase (pos)
pncA (wt)
MGIT (R)
PZase (pos)
pncA (mut)
Susceptible (50) 46 1 - 2 1
MDR-TB (100) 42 9 34 11 4
S; susceptible, R; resistant, PZase; pyrazinamidase assay, MGIT; BACTEC MGIT 960 method, pos; positive, neg; negative, wt; wild-type, mut; mutant
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BACTEC MGIT 960 PZA.
Discussion
Several studies have reported that the prevalence of PZA
resistance ranges from 36% to 54% [14,28,29]. In Thailand,
there is little information on PZA susceptibility. However,
two previous studies have reported the initial PZA resis-
tance to be 6% and 8%, respectively [18,23]. In this study,
PZA susceptibility testing by BACTEC MGIT 960 PZA
revealed 34.6% (52/150) PZA resistance. More specifically,
PZA resistance was found in 6% (3/50) of pan-susceptible
isolates and 49% (49/100) of MDR-TB isolates. The results
were correlated with those obtained from South Africa
indicating 53.3% (68/127) PZA resistance among pre-
viously treated TB patients but a lower resistant rate of
2.1% (1/47) in drug susceptible isolates [14].
PZA resistance is usually associated with defects in
PZase activity. Several studies attempted to detect
enzyme activity and utilised susceptibility testing for
PZA [18,19,21,22]. The sensitivity of the PZase assay
ranged from 79-96%, whereas the specificity was
approximately 98% [20-22]. In this study, PZase activity
was detected in all 98 PZA-susceptible M. tuberculosis
isolates but in only 18 of 52 PZA-resistant isolates. Eigh-
teen isolates with positive PZase activity presented dis-
cordant results with the MGIT 960 PZA system,
resulting in a sensitivity and specificity of 65.4% and
100% for that assay, respectively. The sensitivity of our
PZase assay is low relative to earlier studies. This might
be the result of geographic differences among M. tuber-
culosis isolates. Our isolates may have had alternative
resistant mechanisms, such as insufficient drug uptake
o rt h ep r e s e n c eo fa na c t i v ee f f l u xp u m p[ 1 0 ] ,w h i c h
Table 2 Results of pncA gene sequencing of 150 M. tuberculosis clinical isolates.
M. tuberculosis strains (no. of isolates) MGIT 960 PZase assay pncA mutation
Nucleotide change Amino acid change
Susceptible (46) S + wild-type no
Susceptible (1) S + T92G Ile31Ser
Susceptible (2) R + wild-type wild-type
Susceptible (1) R + T92C Ile31Thr
MDR-TB (42) S + wild-type wild-type
MDR-TB (9) S + T92C Ile31Thr
MDR-TB (34) R - A(-11)G (1) no
A(-11)C (1) no
T56G (1) Leu19Arg
T80C (1) Leu27Pro
T92G (2) Ile31Ser
T104C (1) Leu35Pro
T134C (1) Val45Ala
G136T (1) Ala46Ser
T199C (1) Ser67Pro
C211G (8) His71Asp
G215A (1) Cys72Tyr
G222C (1) Gly74Arg
G289A (3) Gly97Ser
C312G (2) Ser104Arg
G364A (1) Gly122Ser
G373T (1) Val125Phe
G379T (1) Glu 127 Stop
G insertion b/w 411-412 (1)
T416G (1) Val 139 Gly
C425T (1) Thr 142 Met
G436A (1) Ala 146 Thr
C520T (1) Thr 174 Ile
GG insertion b/w 520-521 (1)
MDR-TB (11) R + wild-type no
MDR-TB (4) R + T92C (3) Ile31Thr
T92G (1) Ile31Ser
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was still useful for screening PZA-resistant M. tubercu-
losis isolates and could be used as an alternative
method, particularly for low-income countries where the
assay was highly sensitive.
The major mechanism of PZA resistance was asso-
ciated with mutations of the gene coding for pyrazina-
midase, pncA, in which mutations were scattered along
the coding and promoter regions with high diversity [7].
In this study, mutations were found in 49 isolates, of
which 39 were PZA-resistant and 10 were PZA-suscepti-
ble. However, 17 isolates (7 PZA-resistant and 10 PZA-
susceptible isolates) showed either Ile31Ser or Ile31Thr
mutations. Of these, 15 isolates (except 2 PZA-resistant
isolates) had PZase activity. Previous studies have
demonstrated the catalytic residues of M. tuberculosis
PZase that comprise the active (Asp-8, Trp-68, Lys-96,
Ser-104, Ala-134, Thr-135 and Cys-138) and metal-
binding sites (Asp-49, His-51 and His-71) [30-32].
Taken together with our results, the mutation at Ile-31
did not appear to be associated with PZA resistance.
Notably, two PZA-resistant isolates harboured the Ile31-
Ser mutant but possessed no PZase activity. One possi-
ble scenario is that these 2 isolates might have PZase
activity that is below the limit of detection for the PZase
assay.
Twenty-two of 24 mutation types were detected in
this study and showed a correlation with PZA resistance
(Table 2). Of these, 14 nucleotide substitutions
[13,14,29,33-36] and 2 putative promoter region [9,33]
mutations were previously reported. There were 6 novel
mutation types, consisting of 3 nucleotide substitutions
(Leu27Pro, Gly122Ser, and Thr174Ile), 2 nucleotide
insertions (G insertion between nucleotide 411 and 412
and GG insertion between nucleotide 520 and 521), and
1 nonsense mutation at Glu127. In agreement with ear-
lier studies, the mutations were diverse and scattered
throughout the gene sequence, with the most frequently
occurring mutation being His71Asp (8/49 = 16%). This
is not surprising, as His71 is located in one of the three
preferably mutated regions (positions 3 to 17, 61 to 76,
and 132 to 142) [37] and in the metal-binding site. In
addition, there were 13 PZA-resistant isolates (25%)
with observed PZase activity and no mutations in pncA,
implying that other unknown mechanisms are involved
in PZA resistance.
Conclusions
This study showed the prevalence of PZA resistance in
pan-susceptible and MDR-TB M. tuberculosis clinical
isolates from Siriraj Hospital, Thailand. MDR-TB isolates
had a much higher percentage of PZA resistance (49%)
than susceptible isolates (6%). In this study, the sensitiv-
ities of the PZase assay and pncA sequencing were 65%
and 75%, respectively. The results revealed that 25% of
PZA-resistant isolates had wild-type pncA, indicating
that phenotypic susceptibility testing was still necessary.
Additionally, some pncA mutations are not likely to pro-
duce resistance, limiting the use of genotypic methods
for PZA susceptibility testing. This information is useful
for clinicians in choosing suitable drug regimens for
treating TB patients. This study also indicated that the
automatic addition of PZA in the treatment regimen of
MDR-TB patients would have less benefit in Thailand
and would increase the risk of XDR-TB development or
render treatment ineffective. Therefore, PZA susceptibil-
ity testing in MDR-TB patients should be performed
before starting or adjusting treatment regimens.
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